T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy

Abstract excerpt

There is no readily accessible, scalable cure for HIV infection. Trials of HIV-specific broadly neutralising antibodies (bNAbs) demonstrate inhibition of viral replication and reduction of the reservoir of latently-infected cells, potentially offering new strategies for HIV eradication. Animal and human studies suggest bNAbs have multiple activities, including a direct antiviral action and a secondary induction of...

Topics

Open a Topic to create a Post that cites this publication.

• AIDS Vaccines
• Antibodies, Neutralizing
• B-Lymphocytes
• Cell Lineage
• env Gene Products, Human Immunodeficiency Virus
• HIV/AIDS drug development and treatment
• HIV Research and Treatment
• Monoclonal and Polyclonal Antibodies Research

Identifiers and source

Literature Corpus work

7696d846-723c-5d5c-80d2-31f55d73d3d0

DOI

10.64898/2026.02.02.26345374